Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series.

British journal of cancer - 22 Nov 2016

Carlino Matteo S, Vanella Vito, Girgis Christina, Giannarelli Diana, Guminski Alex, Festino Lucia, Kefford Richard F, Menzies Alexander M, Long Georgina V, Ascierto Paolo A

Abstract excerpt

BACKGROUND: It is unknown whether melanoma patients achieving complete response (CR) with targeted therapy can safely discontinue treatment. METHODS: All patients treated with BRAF/MEK inhibitors achieving CR and ceasing treatment before progression were identified. Clinical data at treatment initiation, cessation and progression were examined. RESULTS: A total of 12 eligible patients were identified, with median...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Antineoplastic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to BRAF gene

Share to Melanoma

Share to Mutation

Share to Proto-Oncogene Proteins B-raf

Share to Recurrence

Share to Survival Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 27711085
DOI: 10.1038/bjc.2016.321
PMCID: PMC5129828

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series.PMID 27711085Read ↗

BRAF inhibitor cessation prior to disease progression in metastatic melanoma: Long-term outcomes.Semantic proximity Read ↗

BRAF/MEK inhibitor rechallenge in advanced melanoma patients.Semantic proximity Read ↗

Long-term outcomes and persistent toxicities following BRAF/MEK inhibitor therapy for advanced melanoma.Semantic proximity Read ↗

Cautious Addition of Targeted Therapy to PD-1 Inhibitors after Initial Progression of BRAF Mutant Metastatic Melanoma on Checkpoint Inhibitor TherapySemantic proximity Read ↗

The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions.Semantic proximity Read ↗

Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma.Semantic proximity Read ↗

Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy.Semantic proximity Read ↗

Intermittent treatment of BRAFV600E melanoma cells delays resistance by adaptive resensitization to drug rechallenge.Semantic proximity Read ↗

Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design.Semantic proximity Read ↗

Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression.Semantic proximity Read ↗

Repeated complete response with long-term control of BRAF-mutant melanoma by multiple rechallenges with dabrafenib plus trametinib.Semantic proximity Read ↗

Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.